Renejix CDMO Partner for Small Molecule Oral Dosage Forms Renejix CDMO Partner for Small Molecule Oral Dosage Forms

X

Find the latest Drugs in Development and Pipeline Prospector News of Orsenix.

  • Webinars & Exhibitions

PharmaCompass
Send me more info on How To Grow My Bussiness Digitally?
Orsenix
United_States_of_America Flag
Country
Country
U.S.A
Address
Address
1105 N. Market Street, Suite 1800, Wilmington, Delaware 19807
Telephone
Telephone
302-510-8961
Linkedin
Linkedin
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Details:

Syros has acquired all assets related to the development and commercialization of SY-2101, including intellectual property, clinical and preclinical data, the regulatory dossier, and product inventory.


Lead Product(s): Arsenic Trioxide

Therapeutic Area: Oncology Product Name: SY-2101

Highest Development Status: Phase IProduct Type: Small molecule

Partner/Sponsor/Collaborator: Syros Pharmaceuticals

Deal Size: $28.0 million Upfront Cash: $12.0 million

Deal Type: Acquisition December 05, 2020

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY